Filing Flows

Filing Flows › 8-K events › Fate Therapeutics

Fate Therapeutics: entry into a material definitive agreement

Form 8-K filed Nov 5, 2026 · items 1.01, 1.02

What the filing says

On November 5, 2026, Fate Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”), with respect to an at-the-market offering program (the “ATM Program”) under which the Company may offer and sell, from time to time at its sole discretion,

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 1.02: 0.0% next session across 2,368. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Item 1.02 — Termination of a material definitive agreement. Ending a material agreement can remove revenue, financing or a planned deal; the filing says who ended it and whether penalties apply.

Fate Therapeutics at a glance

Latest quarterQ2 2026
Revenue$2.1M
Revenue Y/Y+9%
Operating marginn/m
IndustryBiological Products, (No Diagnostic Substances)

Fate Therapeutics, Q2 2026: revenue $2.1M (+9% year over year). The chart follows the revenue to costs, profit and cash.

Fate Therapeutics: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.